Start-Up Eidos Surfs Crest Of TTR Amyloidosis Wave

 
• By Emily Hayes

Emerging Company Profile: The Phase III success of Pfizer's tafamidis means Eidos’ protein misfolding drug AG10 is not the first – but it is validated and differentiated, says BridgeBio-backed start-up Eidos.

Emerging Company Profile Regular column feature image Version 2

More from Start-Ups & SMEs

More from Business